Catalyst Wire Dossier Catalyst Wire Dossier

GAVRETO

pralsetinib · Genentech, Inc.
Drug timelines are a Plus or Pro feature.

14 regulatory and trial events tracked for GAVRETO, covering 2020-09-04 to 2025-12-22. Get the full timeline:

Most recent: FDA Approved: GAVRETO — Supplemental Application (Genentech, Inc.)

See pricing